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Rotterdam, the NetherlandsObjectives This study sought to assess in patients undergoing transcatheter aortic valve implantation
(TAVI), the prevalence and impact of incomplete coronary revascularization deﬁned as >50% coronary
artery or graft diameter stenosis on visual assessment of the coronary angiogram.
Background TAVI is an established treatment option in elderly patients with aortic stenosis (AS) and
a (very) high operative risk. Coronary artery disease (CAD) is often associated with AS.
Methods A single-center cohort of consecutive patients undergoing TAVI between November 2005
and June 2012 was evaluated for the presence of signiﬁcant CAD. The decision to revascularize and
pursue complete revascularization was made by heart team consensus.
Results A total of 263 consecutive patients with a mean age of 80  7 years and 51% male
underwent TAVI with a median follow-up duration of 16 months (interquartile range: 4.2 to
28.1 months). Signiﬁcant CAD with myocardium at risk was present in 124 patients (47%), 44 of whom
had had previous coronary artery bypass grafting (CABG), and the median SYNTAX score in the
81 patients without previous CABG was 9.00 (2.38 to 15.63). Staged percutaneous coronary
intervention (PCI) was planned in 19 (15%) and concomitant PCI with TAVI in 20 (16%). The median
post-procedural residual SYNTAX score of patients without prior CABG was 5.00 (0.13 to 9.88). Overall,
99 patients (37%) (61 with no CABG and 38 CABG patients) had incomplete revascularization
after TAVI. Revascularization status did not affect clinical endpoints. Kaplan-Meier survival curves for
patients with and without complete revascularization demonstrated a 1-year mortality of 79.9% versus
77.4% (p ¼ 0.85), respectively.
Conclusions In an elderly patient population undergoing TAVI for severe AS, a judicious
revascularization strategy selection by a dedicated heart team can generate favorable mid-term
outcome obviating the need for complete coronary revascularization. (J Am Coll Cardiol Intv
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868Transcatheter aortic valve implantation (TAVI) is increas-
ingly offered as a less invasive treatment option for elderly
patients with symptomatic aortic valve stenosis (AS) at higher
operative risk (1–5). Degenerative aortic valve disease shares
similar risk factors with atherosclerotic coronary artery disease
(CAD), and patients with symptomatic AS often have
concomitant CAD (6–9). In surgical series, the presence of
signiﬁcant CAD increases the operative risk and mortality of
surgical aortic valve replacement (SAVR), both when left
untreated and when treated with concomitant coronary artery
bypass grafting (CABG) (10–13). According to guidelines on
valvular heart disease, concomitant CAD should be treated
while performing SAVR (14,15). The impact of CAD in
patients undergoing TAVI is not well established. In the
randomized PARTNER (Placement of Aortic Transcatheter
Valves) trial, patients with signiﬁcant CAD requiring revas-
cularization therapy were excluded from the trial (16,17).
Retrospective TAVI studies remain equivocal but tend toAbbreviations
and Acronyms
ACS = acute coronary
syndrome
AS = aortic valve stenosis
CABG = coronary artery
bypass grafting
CAD = coronary artery
disease
IQR = interquartile range
PCI = percutaneous coronary
intervention
SAVR = surgical aortic valve
replacement
TAVI = transcatheter aortic
valve implantationsuggest that presence of CAD or
non-revascularized myocardium
is not associated with worse out-
come (18–23).
The SYNTAX (SYNergy be-
tween percutaneous coronary inter-
vention with TAXus and cardiac
surgery) trial introduced the
SYNTAX score to assess the
extent and complexity of sig-
niﬁcant CAD (24). Incomplete
revascularization was associated
with worse outcome. Further-
more, in acute coronary syndrome
(ACS) patients undergoing per-
cutaneous coronary intervention
(PCI), a residual SYNTAX score
to evaluate untreated lesions alsopredicts short- and longer-term prognosis (25). The aim
of this study was to assess the prevalence and impact of
incomplete revascularization in patients undergoing TAVI.
Methods
The study population consisted of all consecutive patients
with symptomatic severe AS who underwent TAVI between
November 2005 and June 2012 in the Erasmus Medical
Center, Rotterdam, the Netherlands. All potential TAVI
candidates underwent a detailed multidisciplinary and mul-
timodality imaging assessment. Over the course of the
TAVI program, a dedicated heart team was installed con-
sisting of at least 1 interventional cardiologist, 1 cardiac
surgeon, and 1 imaging specialist and was completed with an
anesthesiologist, geriatrician, or neurologist upon indication.
The heart team convened on a weekly basis and conﬁrmed
a patient’s eligibility for TAVI based on a critical appraisal ofestablished risk scores (STS, Logistic EuroSCORE),
assessment of risk variables not included in these models,
anatomical considerations, and clinical judgment. In prin-
ciple, patients needed to be at high or prohibitive operative
risk. Invasive coronary angiography was mandatory in all
patients and was assessed in the heart team discussion.
In case of signiﬁcant CAD (i.e., >50% diameter stenosis
on visual assessment of the coronary angiogram), the treat-
ment strategy and completeness of revascularization was
determined based on consensus decision before the
TAVI procedure, taking into consideration infarcted area,
viable myocardial tissue at risk, and technical complexity.
Myocardium at risk was not formally quantitated by
myocardial imaging but was estimated by visual assessment
of the presence of obstructive atherosclerotic disease in
coronaries supplying noninfarcted myocardial territories.
The revascularization options were: 1) staged PCI before
the TAVI procedure; 2) PCI concomitant with the TAVI
procedure; and 3) conservative approach (no PCI).
Baseline characteristics, procedural data, and outcome data
were prospectively collected in a dedicated database in
accordance with local institutional review board guidelines.
All in-hospital clinical endpoints are deﬁned according to
the Valve Academic Research Consortium criteria (26). Per
protocol, clinical follow-up visits were scheduled at 6 weeks, 6
months, 12 months, and yearly thereafter. Survival was ob-
tained from the Dutch Civil Registry. Clinical follow-up was
derived by reviewing hospital charts and contacting referring
physicians and patients’ general practitioners.
For the purpose of this study, all baseline diagnostic
angiograms were re-assessed to capture baseline coronary
status. Distinction was made between patients with and
without previous CABG. In patients with previous CABG,
completeness of revascularization was assessed by evaluating
the native coronary circulation and the respective grafts. For
patients without previous CABG, including those with prior
PCI, the SYNTAX score was calculated. In patients with
signiﬁcant CAD after the previous CABG, or a SYNTAX
score >0, treatment strategy was documented as staged
intervention, concomitant intervention, or no intervention.
After the TAVI procedure, the completeness of revascular-
ization was re-assessed: a residual SYNTAX score was
calculated in the no-CABG cohort. During follow-up,
the need for additional coronary interventions, indication
(elective or acute coronary syndrome), and success of PCI
after TAVI was assessed.
TAVI procedure. TAVI procedural details have been exten-
sively described before (27). During the TAVI procedure, all
patients were on full-dose aspirin and clopidogrel. Patients
were loaded with 300mg of aspirin and 300mg of clopidogrel
1 day before the TAVI. Procedural anticoagulation was ob-
tained with a heparin bolus of 70 IU/kg, aiming for an acti-
vated clotting time of 250 to 300 ms. The 2 commercially
available TAVI platforms, the Medtronic CoreValve system
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869(Medtronic, Minneapolis, Minnesota) and the Edwards
SAPIEN valve (Edwards Lifesciences, Irvine, California),
were used. The transfemoral approach was the access strategy
of ﬁrst choice, followed by the transaxillary and transapical
routes. PCI was executed according to standard practice and
always before the actual valve implantation. Drug-eluting
stents were the stent platform of ﬁrst choice, and patients
continued dual antiplatelet therapy for 1 year after PCI.
Statistical analysis. Categorical variables are presented as
frequencies and percentages, and were compared with the
use of the Pearson chi square test or the Fisher exact
test, as appropriate. Continuous variables are presented as
mean  SD (in case of a normal distribution) or median




Age, yrs 80.3  7.0
Male 134 (51.0)
Height, cm 167.31  9.15
Weight, kg 74.05  12.92
Body mass index, kg/m2 26.46  4.18
Body surface area, m2 1.85  0.19
New York Hearth Association class III or IV 223 (84.8)
Logistic EuroSCORE 17.63  10.41
Frailty 83 (31.6)
Antecedents
Previous cerebrovascular accident 62 (23.6)
Previous myocardial infarction 66 (25.1)
Previous CABG 70 (26.6)
Previous percutaneous coronary intervention 73 (27.8)
CAD 175 (66.5)
SYNTAX score y
Diabetes mellitus 70 (26.6)
Hypertension 162 (61.6)
Glomerular ﬁltration rate 60 ml/min 137 (52.1)
Chronic hemodialysis 10 (3.8)
Chronic obstructive pulmonary disease 70 (26.6)
Peripheral vascular disease 39 (14.8)
Permanent pacemaker 23 (8.7)
Atrial ﬁbrillation 76 (28.9)
Baseline echocardiography
Aortic valve area, cm2 0.66  0.21
Left ventricular ejection fraction, % 50.54  14.40
Aortic annulus diameter, mm 22.57  2.38
Peak velocity 4.26  0.76
Peak gradient, mm Hg 75.17  26.39
Mean gradient, mm Hg 44.78  16.74
Aortic regurgitation grade III 44 (16.9)
Mitral regurgitation grade III 27 (10.4)
Values are mean  SD, n (%), or median (interquartile range). *Combination of previous CABG, myocardia
SYNTAX score is not reported.
CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease.and compared with the use of the Student t test or the
Mann-Whitney U test. Normality of the distributions was
assessed using the Shapiro-Wilks test. Kaplan-Meier curves
were generated to assess estimates of survival. A 2-sided
alpha level of 0.05 was used for all superiority testing. All
statistical analysis were performed with the use of SPSS
software version 17.0 (SPSS, Chicago, Illinois).
Results
A total of 263 consecutive patients underwent TAVI with
a median follow-up duration of 16 months (IQR: 4.2 to
28.1 months). Baseline and procedural characteristics are




(n ¼ 124) p Value
80.0  7.6 80.5  6.4 0.58
59 (42.4) 75 (60.5) 0.002
166.77  9.05 167.92  9.25 0.31
73.49  13.26 74.68  12.55 0.46
26.440  4.26 26.49  4.10 0.92
1.84  0.20 1.86  0.19 0.35
117 (84.2) 106 (85.5) 0.77
16.13  9.97 19.32  10.66 0.013
47 (33.8) 36 (29.0) 0.41
25 (18.0) 37 (39.8) 0.024
24 (17.3) 42 (33.9) 0.002
26 (18.7) 42 (35.5) 0.002
23 (16.5) 50 (40.3) <0.001
51 (36.7) 124 (100.0) <0.001
0 9.00 (2.38–15.63) <0.001
35 (25.2) 35 (28.2) 0.58
76 (54.7) 86 (69.4) 0.02
62 (44.6) 75 (60.5) 0.01
5 (3.6) 5 (4.0) 0.85
38 (27.3) 32 (25.8) 0.78
11 (7.9) 28 (22.6) 0.001
12 (8.6) 11 (8.9) 0.95
47 (33.8) 29 (23.4) 0.06
0.66  0.21 0.66  0.21 0.93
52.71  13.97 48.18  14.55 0.017
22.60  2.54 22.52  2.20 0.85
4.37  0.77 4.123  0.72 0.009
78.97  27.50 70.90  24.49 0.014
47.12  17.35 42.13  15.69 0.018
26 (19.0) 18 (14.6) 0.35
19 (13.9) 8 (6.5) 0.06
l infarction, percutaneous coronary intervention, or current SYNTAX score >0. yThe overall median
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87051% were male. Mean Logistic EuroSCORE was 17.63 
10.41%; a transfemoral percutaneous access strategy was used
in 95% of patients. The Medtronic CoreValve was the
predominant device platform. Two-thirds of all patients (175
of 263 patients) had a history of past or current CAD with
previous PCI or CABG in 28% and 27%, respectively, of the
patients and a previous myocardial infarction in 25%. At
baseline, obstructive atherosclerotic disease in coronary arteries
supplying noninfarcted myocardial territories was present in
124 patients (47%), 44 of whom (35%) had had previous
CABG. Nine patients initially presented with an ACS: 6 with
unstable angina/non–ST-segment elevation myocardial in-
farction and 3 with ST-segment elevation myocardial infarc-
tion. Male sex, hypertension, chronic kidney disease, and
low left ventricular ejection fraction were more prevalent in
patients with incomplete revascularization at baseline.
Revascularization status. All patients who initially presented
with an ACS were treated with ad hoc PCI followed by







Surgicaldfemoral artery 10 (3.8)
Percutaneousdfemoral artery 239 (90.9) 1
Surgicaldsubclavian artery 3 (1.1)






None 245 (93.2) 1
Additional interventions during TAVI
PTA iliac artery 6 (2.3)
Prosthesis Size
Medtronic CoreValve, 26 mm* 83 (31.6)
Medtronic CoreValve, 29 mm* 153 (58.2)
Medtronic CoreValve, 31 mm* 9 (3.4)
Edwards SAPIEN, 23 mm* 5 (1.9)
Edwards SAPIEN, 26 mm* 10 (3.8)
Therapy-speciﬁc results
Post-implantation balloon dilation 46 (17.5)
Valve-in-valve implantation 12 (4.6)
Coronary obstruction 1 (0.4)
Ventricular perforation 3 (1.1)
Conversion to surgical AVR 1 (0.4)
Procedure time, min 208.78  66.71 212
Amount of contrast, ml 159.73  78.45 160
Values are n (%) or mean  SD. *3 patients did not undergo ﬁnal implantation; 1 died during induction (a
and 1 had a major vascular complication upon access.
AVR ¼ aortic valve replacement; ECMO ¼ extra corporeal membrane oxygenation; IABP ¼ Intra-aor
intervention; PTA ¼ percutaneous transluminal angioplasty; TAVI ¼ transcatheter aortic valve implantaprior CABG, 44 (63%) had incomplete revascularization at
the time of heart team presentation because of progressive
native CAD or saphenous vein graft disease. Revasculari-
zation was planned in 6 (14%): staged PCI in 5 and
concomitant with the TAVI procedure in 1. All 6 patients
obtained complete revascularization (Fig. 1). A total of 80
patients with no history of prior CABG had incomplete
revascularization at baseline, with a median SYNTAX score
of 9.00 (2.38 to 15.63). PCI TAVI was planned in
33 patients (41% of patients with a SYNTAX score >0):
staged in 14 (17%) and concomitant with TAVI in
19 (24%). The median residual SYNTAX score after TAVI
was 5.00 (0.13 to 9.88). The change in SYNTAX score in
the no-CABG patients who were planned for PCI and were
incompletely revascularized is shown in Figure 2. Overall,
99 patients (38%) (61 with no-CABG and 38 CABG
patients) were incompletely revascularized after TAVI.
Endpoints. Clinical follow-up was complete for all patients.




(n ¼ 124) p Value
8 (5.8) 2 (1.6) 0.08
28 (92.1) 111 (89.5) 0.47
0 3 (245) 0.07
2 (1.4) 3 (2.4) 0.56
1 (0.7) 5 (4.0) 0.07
2 (1.4) 0 0.18
6 (4.3) 9 (7.3) 0.31
0 1 (0.8) 0.29
31 (94.2) 114 (91.9) 0.46
3 (2.2) 3 (2.4) 0.89
45 (32.4) 38 (30.6) 0.76
79 (56.8) 74 (59.7) 0.64
4 (2.9) 5 (4.0) 0.61
3 (2.2) 2 (1.6) 0.75
5 (3.6) 5 (4.0) 0.85
21 (15.1) 25 (20.2) 0.28
7 (5.0) 5 (4.0) 0.70
0 1 (0.8) 0.29
1 (0.7) 2 (1.6) 0.50
1 (0.7) 0 0.34
.24  67.41 204.88  66.00 0.40
.64  81.24 158.75  75.75 0.86
nesthesia), 1 died as a result of balloon valvuloplasty–induced left ventricular outﬂow tract rupture,
tic balloon counterpulsation; LVAD ¼ left ventricular assist device; PCI ¼ percutaneous coronary
tion.
Figure 1. Revascularization Status Pre- and Post-TAVI in Patients With
Signiﬁcant CAD at Baseline
Blue: cohort with SYNTAX score >0 at baseline; red: cohort with prior CABG
and incomplete revascularization at baseline. CABG ¼ coronary artery bypass
grafting; CAD ¼ coronary artery disease; TAVI ¼ transcatheter aortic valve
implantation.
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871according to the presence of incomplete revascularization.
There were no relevant differences among the respective
cohorts. Procedural time and total contrast volume were
similar. There were no differences in cardiac enzyme rise
between patients with or without CAD, or whether patients
obtained complete revascularization or not. Remarkably,
during follow-up, no evident residual angina was noted.
Survival curves for patients with and without complete
revascularization at baseline or after TAVI, and for patients
with residual SYNTAX score <8 versus 8 are displayed in
Figure 3. No signiﬁcant differences were found in overall
survival.
PCI post-TAVI. Eight patients underwent PCI a median of
140 days (IQR: 0 to 337 days) after TAVI. All except 1 wereFigure 2. Reduction in SYNTAX Score in Patients Undergoing PCI Pre-TAVI
The red line marks the change in mean score. PCI ¼ percutaneous coronary
intervention; TAVI ¼ transcatheter aortic valve implantation.prior Medtronic CoreValve cases. Two patients had no CAD
(SYNTAX score ¼ 0) before the TAVI procedure, and 5
patients had accepted incomplete revascularization (3 after
previous CABG). One patient with staged left main coronary
artery PCI had a late stent thrombosis 126 days after TAVI
while still on dual antiplatelet therapy. One patient had
a TAVI procedure–related dissection of the left main stem
and underwent intravascular ultrasound–guided PCI 1 day
after TAVI (28). One patient presented with a troponin rise,
yet the coronary angiogram and intravascular ultrasound
examination showed no obvious disease progression. Prag-
matically, a balloon dilation was performed on the known
ostial right coronary artery lesion. Two patients presented
with a ST-segment elevation myocardial infarction: 1 with an
acute occlusion of a saphenous vein graft, the other with
a de novo thrombotic occlusion of the proximal left ante-
rior descending coronary artery. Two PCI procedures were
complicated by a neurological event (1 major stroke, and
1 transient ischemic attack).
Discussion
Our study on 263 consecutive elderly high-risk TAVI
patients highlights: 1) incomplete coronary revascularization
at baseline is common; 2) revascularization strategy based on
heart team consensus is feasible; and 3) when revasculari-
zation strategy is based on heart team consensus, complete
revascularization is not a prerequisite for good medium-term
prognosis.
Prevalence of CAD in patients with AS. The prevalence of
signiﬁcant CAD in our study is similar to what has been
reported in other TAVI registries, yet appears somewhat
higher than what is reported in the surgical literature,
indicating CAD in 30% to 50% of patients who undergo
SAVR (20,22). An overall older study population and the
fact that patients with advanced comorbidities may also have
more CAD may explain a higher prevalence of CAD in
current TAVI practice. Also, patients with antecedents of
complex CAD, including previous revascularization thera-
pies, may be driven in the direction of TAVI.
Treatment strategy for AS in combination with CAD. Data on
the need for combined CABG with SAVR in case of severe
AS with concomitant signiﬁcant CAD are relatively scarce
but seem to suggest its merits (13,29). Concomitant CABG
may improve short- and long-term survival, and reduce the
risk for perioperative myocardial infarction (30,31). As such,
it has been adopted in international guidelines on valvular
heart disease (14,15). Conversely, a cohort study from the
Northern New England Cardiovascular Disease Study
Group on 7,584 consecutive patients undergoing SAVR
suggested concomitant CABG did not impact survival in
octogenarians as opposed to patients <80 years of age (32).
These ﬁndings are corroborated by Maslow et al. (33),
conﬁrming there was no difference in long-term survival
Table 3. VARC Endpoints Dichotomized According to Completeness of Coronary Revascularization





30-day or in-hospital death
All-cause 17 (6.5) 9 (6.5) 8 (6.5) 0.99
Cardiovascular 12 (4.6) 8 (5.8) 4 (3.2) 0.33
Myocardial Infarction
Periprocedural (<72 h) 2 (0.8) 1 (0.7) 1 (0.8) 0.94
Spontaneous (>72 h) 0 0 0 1.00
Cerebrovascular complication
Major stroke 14 (5.3) 8 (5.8) 6 (4.8) 0.74
Minor stroke 2 (0.8) 0 2 (1.6) 0.13
Transient ischemic attack 5 (1.9) 4 (2.9) 1 (0.8) 0.22
Vascular complication
Major 17 (6.5) 10 (7.2) 7 (5.6) 0.61
Minor 25 (9.5) 20 (14.4) 5 (4.0) 0.004
Bleeding complication
Life threatening 21 (8.0) 14 (10.1) 7 (5.6) 0.19
Major 34 (12.9) 26 (18.7) 8 (6.5) 0.003
Minor 26 (9.9) 18 (12.9) 8 (6.5) 0.08
Acute kidney injury
Stage I 37 (14.1) 18 (12.9) 19 (15.3) 0.58
Stage II 6 (2.3) 3 (2.2) 3 (2.4) 0.89
Stage III 4 (1.5) 2 (1.4) 2 (1.6) 0.91
Reintervention in hospital 2 (0.8) 2 (1.4) 0 0.18
Length of stay
Total hospitalization 8.0 (4.5–11.5) 9.0 (5.0–13.0) 8.0 (4.5–11.5) 0.14
Prosthetic valve–associated complications
New permanent pacemaker requirement 52 (19.8) 27 (19.4) 25 (20.3) 0.86
Combined endpoints
Composite safety endpoint 55 (22.0) 31 (23.3) 24 (20.5) 0.59
Values are n (%) or median (interquartile range).
VARC ¼ Valve Academic Research Consortium.
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872between isolated SAVR and SAVR combined with CABG
in octogenarians.
A pooled analysis of 2 TAVI feasibility registries
including 201 high-risk patients suggested that a history of
previous cardiovascular intervention was associated with
increased short- and long-term mortality and a more than
2 times higher risk of dying at any point (21). However, no
data from invasive coronary angiograms were available, and
concomitant PCI and TAVI was not allowed. In the early
Vancouver experience of 136 patients, 76% had coexisting
CAD. Presence of CAD or non-revascularized myocardium
as determined by the Duke Myocardial Jeopardy score was
not associated with an increased risk of adverse events up to
1 year (23).
The Italian CoreValve Registry enrolling 663 consecutive
patients with previous PCI or CABG in 38% of cases did
not ﬁnd any impact of previous coronary intervention on
1-year clinical outcome (19). The German TAVI Registry,
including 1,382 patients (82% CoreValve) with CAD
(deﬁned as angiographically determined coronary stenosis50%) present in 62%, did not discriminate between
patients who underwent PCI in preparation for TAVI
(staged PCI) or with a past history of PCI (20). Patients with
CAD had a lower ejection fraction and a greater proportion
of ejection fraction <30%. Concomitant PCI was performed
in only 5.5% of patients with CAD. By multivariate analysis,
CAD was not associated with in-hospital mortality.
A single-center experience including 125 patients adopted
a strategy of PCI of all signiﬁcant epicardial lesions before
TAVI. Fifty-ﬁve patients required PCI, all but 3 as a staged
procedure with a median time interval between PCI and
TAVI of 10 days (34). No data were provided on PCI
success and actual completeness of revascularization. The
need for PCI was not associated with 30-day or 6-month
adverse event rates.
The timing of elective PCI in patients planned for TAVI
is essential in the heart team decision-making process
and requires consideration of patient characteristics (age,
frailty, renal function, etc.) and procedural complexity. In
comparison with concomitant PCI and TAVI, a 2-step
Figure 3. Kaplan-Meier Survival Curves
(A) Patients with complete (blue) versus incomplete (red) revascularization after TAVI. (B) Patients with complete (blue) versus incomplete revascularization (red)
before TAVI. (C) Patients with incomplete revascularization before and after TAVI (red) versus patients with complete revascularization (black) versus patients with
incomplete revascularization before TAVI who acquired complete revascularization after TAVI (blue). (D) Patients with incomplete revascularization after TAVI and
residual SYNTAX score 8 (red) versus <8 (blue). TAVI ¼ transcatheter aortic valve implantation.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 8 , 2 0 1 3 Van Mieghem et al.
A U G U S T 2 0 1 3 : 8 6 7 – 7 5 Coronary Revascularization Status and TAVI
873approach may result in relative reduction in procedure time
and radiation and contrast exposure, yet demands arterial
access twice with the inherent risk for vascular and bleeding
complications and may come with additional hospitalization
costs.
Our strategy on concomitant CAD with TAVI reﬂects
what has been reported by the Bern group. In the Bern
TAVI registry on 265 TAVI patients, 65% had CAD,
deﬁned as a signiﬁcant stenosis >50% or previous revascu-
larization therapy, 35% of whom underwent staged (n ¼ 23
patients) or concomitant (n ¼ 36) PCI (22). PCI in addition
to TAVI did not have an impact on outcome. Also, patients
with signiﬁcant CAD who did not undergo PCI had similar
outcomes as compared with TAVI in patients without
CAD. No information was provided related to completeness
of revascularization in patients undergoing staged orconcomitant PCI. We used the residual SYNTAX score to
characterize residual stenosis after PCI. The median post-
procedural residual SYNTAX score of patients without prior
CABG was 5.00 (0.13 to 9.88). Complete revascularization
was achieved in 20% of TAVI patients with incomplete
revascularization at baseline. The residual SYNTAX score
may help in risk stratifying patients for future coronary
events. In moderate- to high-risk ACS patients, a residual
SYNTAX score (rSS) >8 was associated with poor 30-day
and 1-year survival (25). We could not detect any impact of
the residual SYNTAX score in our series. In principle, ACS
and TAVI populations differ signiﬁcantly because in the
latter, there is no acute clinical event and patients are
older. The importance of age on the impact of incomplete
revascularization has been suggested in a French study
on patients undergoing CABG, which found incomplete
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874revascularization did not have an impact on survival in
patients >60 years of age, suggesting that in this particular
elderly patient population at high operative risk, limited
coronary revascularization may be considered when deemed
necessary (35). It may be safe to waive variable degrees of
CAD without intervention, and pursuit of complete revas-
cularization is not a prerequisite for medium-term clinical
success in an elderly AS patient population, provided a
rational and pragmatic approach to CAD by a dedicated
heart team is guaranteed. Finally, using this selective revas-
cularization strategy, the urge for PCI after TAVI is limited,
and although it is technically feasible, may be associated
with associated morbidity as suggested by 2 neurological
events in our series.
Study limitations. In this single-center study, extent and
complexity of CAD were assessed by retrospectively calcu-
lating the SYNTAX score, yet baseline characteristics and
clinical endpoints were prospectively collected. Scoring
relied exclusively on visual assessment of the diagnostic
angiograms. Fractional ﬂow reserve was only used in a
minority of cases but may certainly downgrade the extent of
CAD. The median follow-up duration of 16 months
provides insights into the impact of CAD in the mid-term,
yet precludes extrapolation to longer-term follow-up. Given
the relatively small sample size, our data should be inter-
preted with caution and demand conﬁrmation in larger
(preferably randomized) studies.
Conclusions
In an elderly patient population undergoing TAVI for
severe AS, incomplete coronary revascularization is a domi-
nant baseline feature. Judicious revascularization strategy
selection by a dedicated heart team can generate favorable
mid-term outcomes, obviating the need for complete coro-
nary revascularization.
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